Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease

Pieter Hindryckx, Gregor Novak, Stefanos Bonovas, Laurent Peyrin-Biroulet, Silvio Danese

Research output: Contribution to journalReview articlepeer-review


The development of biologic drugs revolutionized the management of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. However, while their efficacy has been well established, it remains uncertain to what extent biologic treatments may be associated with important safety risks, such as serious infections, opportunistic infections, or tuberculosis reactivation. Herein, we review and discuss the current evidence on the infection risk associated with biologic therapy in patients with inflammatory bowel disease (IBD).

Original languageEnglish
Pages (from-to)633-641
Number of pages9
JournalClinical Pharmacology and Therapeutics
Issue number4
Publication statusPublished - Oct 1 2017

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease'. Together they form a unique fingerprint.

Cite this